Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi
Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi
复制标题
肝细胞癌累及胆管癌栓的临床病理特征及肝干细胞标志物表达
DOI：
10.1007/s13277-015-4446-3
复制
发表时间：
2016-05-01
期刊：
影响因子：
--
通讯作者：
Li, Le-Qun
中科院分区：
文献类型：
--
作者：
Pang, Ye-Bin;Zhong, Jian-Hong;Li, Le-Qun
本研究旨在分析累及胆管癌栓（BDTT）的肝细胞癌（HCC）的临床病理特征及肝干细胞标志物的表达情况。对连续接受手术治疗的 HCC 患者系列中总共 35 名患有 HCC 和 BDTT 的患者进行回顾性研究，并与同系列中 916 名无 BDTT 的患者进行比较。比较两组患者的临床病理特征、总生存期（OS）以及肝脏干细胞标志物CD133、CD90、EpCAM、CK19、VEGF和C-kit的肿瘤表达。对整个患者组以及 35 对有或没有 BDTT 且与倾向评分相匹配的患者进行了分析。接受 BDTT 的 HCC 患者往往比未接受 BDTT 的患者肿瘤更小，并且出现低分化肿瘤、Child-Pugh B 级、肝硬化和微血管侵犯的可能性更高。 BDTT 患者的肿瘤组织中所有检查的肝干细胞标志物的表达率均显着升高。 BDTT 患者的 OS 在 1 年（69 vs 84%）、3 年（37 vs 64%）和 5 年（20 vs 55%）时显着较低（P< 0.001）。患有 HCC 和 BDTT 的患者的 OS 低于没有 BDTT 的患者。 BDTT 存在时肝脏干细胞标志物表达频率较高，表明此类干细胞可能在这种 HCC 的发病机制中发挥作用。
The aim of this study was to analyze the clinicopathological characteristics and expression of liver stem cell markers of hepatocellular carcinoma (HCC) involving bile duct tumor thrombi (BDTT). A total of 35 patients with HCC and BDTT in a consecutive series of HCC patients who underwent surgical treatment were studied retrospectively and compared with 916 patients without BDTT from the same series. Clinicopathological characteristics, overall survival (OS), and tumor expression of liver stem cell markers CD133, CD90, EpCAM, CK19, VEGF, and C-kit were compared between the two patient groups. Analysis was performed for the entire patient groups as well as for 35 pairs of patients with or without BDTT matched by propensity score. HCC patients with BDTT tended to have smaller tumors than those without BDTT, as well as a higher probability of having poorly differentiated tumor, Child-Pugh class B, liver cirrhosis, and microvascular invasion. Tumor tissue in patients with BDTT showed significantly higher expression rates of all liver stem cell markers examined. OS was significantly lower for patients with BDTT at 1 year (69 vs 84 %), 3 years (37 vs 64 %), and 5 years (20 vs 55 %) (P< 0.001). Patients with HCC and BDTT show lower OS than patients without BDTT. The higher frequency of liver stem cell marker expression in the presence of BDTT suggests that such stem cells may play a role in the pathogenesis of this form of HCC.